Updated guidelines target co-infected HIV, TB patients
Previously published reports provided clinicians with guidelines for managing pharmacologic interactions that can result from concomitant protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) and rifamycin therapy. A group of CDC scientists and outside expert consultants recently updated the guidelines. The revised guidelines are available at http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
